Financial Performance - The company's operating revenue for 2022 was RMB 1,792,000,925.51, representing a 14.36% increase from RMB 1,566,972,727.99 in 2021 [25]. - Net profit attributable to shareholders for 2022 was RMB 285,851,485.43, a significant increase of 308.12% compared to RMB 70,040,562.22 in 2021 [26]. - The basic earnings per share for 2022 was RMB 0.66, reflecting a 312.50% increase from RMB 0.16 in 2021 [27]. - The total assets at the end of 2022 amounted to RMB 2,922,150,136.69, an 8.05% increase from RMB 2,704,474,688.10 at the end of 2021 [26]. - The net cash flow from operating activities for 2022 was RMB 301,625,891.42, which is a 62.49% increase from RMB 185,626,591.50 in 2021 [26]. - The weighted average return on equity for 2022 was 19.24%, up from 5.98% in 2021, indicating a significant improvement [27]. - The net profit after deducting non-recurring gains and losses for 2022 was RMB 106,519,926.79, a 69.03% increase from RMB 63,020,050.07 in 2021 [26]. - The company's net assets attributable to shareholders at the end of 2022 were RMB 1,390,129,348.50, a 16.23% increase from RMB 1,196,044,862.87 at the end of 2021 [26]. Dividend and Shareholder Returns - The board approved a cash dividend of 2.60 CNY per 10 shares for all shareholders, subject to shareholder meeting approval [5]. Audit and Compliance - The financial report was audited and received a standard unqualified opinion from the accounting firm [4]. - The company has not reported any significant differences in governance compared to regulations set by the China Securities Regulatory Commission [167]. - The company has not reported any related party transactions that could affect its independence [167]. Market Strategy and Growth - The company plans to continue expanding its market presence and investing in new product development to sustain growth [27]. - The company aims to enhance its core competitiveness through innovation in traditional Chinese medicine and management transformation [71]. - The company is actively pursuing market expansion through the establishment of new subsidiaries and related transactions [188]. - The company plans to enhance academic promotion and terminal coverage for its pediatric product, Xiaoer Jingxing Cough Granules, to boost sales growth [60]. - The company aims to develop 3 products with a revenue of 1 billion, 3 products with 500 million, and 8 products exceeding 100 million within the next 5-10 years as part of the "338 Major Product Development Plan" [150]. Research and Development - The company has established an Innovation Research Institute to enhance R&D capabilities, focusing on a multi-center development model for innovative traditional Chinese medicine [151]. - The company focuses on the research and development of traditional Chinese medicine and has developed several brand series, including "Xinxuean" for cardiovascular diseases and "Jinbeibei" for pediatrics [71]. - The company has 141 drug registration certificates and 17 new drug certificates, indicating a strong product reserve to support strategic goals [72]. - The company is actively involved in various clinical trials, including the ongoing clinical research for the pediatric cough granules and the application review for Nolitong granules [134]. Operational Efficiency - The company has successfully reduced production costs for key raw materials, enhancing overall profitability and operational efficiency [37]. - The company has implemented a comprehensive safety management system, achieving a 100% safety hazard rectification rate and no major safety incidents during the reporting period [43]. - The company has initiated a group management enhancement project to optimize organizational structure and improve operational efficiency [44]. Employee Management and Development - The company has focused on talent acquisition and training, establishing a performance-based incentive system to enhance employee engagement and loyalty [45]. - The company emphasizes a performance-oriented "three-dimensional" incentive system to enhance employee motivation and align with long-term development goals [199]. - Comprehensive training programs are provided to support employees' career development and skill enhancement [200]. Industry Trends and Market Conditions - The pharmaceutical industry in China continues to grow, supported by government policies promoting research and innovation, with a strong emphasis on traditional Chinese medicine [46]. - The total revenue of the top 100 pharmaceutical companies in China reached CNY 1,076.2 billion in 2021, marking a year-on-year growth of 19.40% [52]. - The market for pediatric traditional Chinese medicine (TCM) has shown stable growth, with a terminal sales scale of 10.4 billion RMB in 2021, a 43% increase from 2015 [58]. Financial Management - The company reported a significant increase in contract liabilities, which rose by 149.26% to ¥87.45 million, mainly due to pre-receipts from customers [110]. - The company’s total liabilities decreased by 52.60% to ¥210.25 million, reflecting a strategic adjustment in its borrowing structure [110]. - The company has made provisions for asset impairment and bad debt reserves in its financial reports [186]. Governance and Board Activities - The company conducted 16 board meetings and 13 supervisory meetings during the reporting period, ensuring compliance with legal and regulatory requirements [163][164]. - The company held a total of 3 shareholder meetings during the reporting period, with all proposed resolutions approved [169]. - The company has undergone changes in its board composition, with several members resigning and new members being elected [183]. Future Outlook - Future outlook indicates a projected revenue growth of 15% for the next fiscal year, driven by new product launches and market expansion strategies [173]. - The company anticipates a recovery in the pharmaceutical industry, driven by ongoing reforms and policy support, indicating a positive outlook for growth in the sector [148].

2022-001 证券代码：603998 证券简称：方盛制药 湖南方盛制药股份有限公司 投资者关系活动记录表 编号： | --- | --- | --- | |-----------------------|------------------------------|--------------------------------------------------------------| | | 特定对象调研 | 分析师会议 | | | 媒体采访 | 业绩说明会 | | 投资者关系活动 | 新闻发布会 | 路演活动 | | 类别 | 现场参观 | 电话会议 | | | 其他 | | | 参与单位名称 | | | | （排名不分先 | | 华安证券、瀚伦投资、永赢基金、红土创新、长安基金 | | 后） | | | | 时间 2022 | 年 4 月 29 | 日 14:00-15:00 | | | 地点 公司会议室 | | | 会议形式 电话会议 | | | | 上市公司接待人 员姓名 | | 董事会秘书何仕、证券事务代表曾博茹 | | | 主要交流内容： | | | | | 一、公司业务情况介绍 | | ...

证券代码：603998 证券简称：方盛制 药 湖南方盛制药股份有限公司 投资者关系活动记录表 编号： 2022-002 | --- | --- | --- | |-------------------|----------------------|------------------------------------------------------------| | | 特定对象调研 | 分析师会议 | | | 媒体采访 | 业绩说明会 | | 投资者关系活动 | 新闻发布会 | 路演活动 | | 类别 | 现场参观 | 电话会议 | | | 其他 | | | | | 华鑫证券、富唐资产、诺德基金、金百镕投资、天弘基金、君和资 | | 参与单位名称 | | 本、嘉合基金、上海天猊投资、中新融创、中科沃土、中原英石基 | | （排名不分先 | | 金、国海富兰克林、华宝信托、南方睿泰基金、理成资产、上海国 | | 后） | 际信托、泰康资产等 | | | 时间 2022 | 年 5 月 5 日 | 10:30-11:30 | | | 地点 公司会议室 | | | 会议形式 电话会议 | | | | 上市公 ...

2022-001 证券代码：603998 证券简称：方盛制药 湖南方盛制药股份有限公司 投资者关系活动记录表 编号： | --- | --- | --- | |-----------------------|------------------------------|--------------------------------------------------------------| | | 特定对象调研 | 分析师会议 | | | 媒体采访 | 业绩说明会 | | 投资者关系活动 | 新闻发布会 | 路演活动 | | 类别 | 现场参观 | 电话会议 | | | 其他 | | | 参与单位名称 | | | | （排名不分先 | | 华安证券、瀚伦投资、永赢基金、红土创新、长安基金 | | 后） | | | | 时间 2022 | 年 4 月 29 | 日 14:00-15:00 | | | 地点 公司会议室 | | | 会议形式 电话会议 | | | | 上市公司接待人 员姓名 | | 董事会秘书何仕、证券事务代表曾博茹 | | | 主要交流内容： | | | | | 一、公司业务情况介绍 | | ...

证券代码：603998 证券简称：方盛制药 编号：2022-003 湖南方盛制药股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-----------------------|------------------------------------------------------------------|-----------------------------------------------------------------------------------------| | 投资者关系活动 \n类别 | 特定对象调研 \n 媒体采访 \n 新闻发布会 \n 现场参观 \n 其他 | 分析师会议 \n 业绩说明会 \n 路演活动 \n 电话会议 | | 参与单位名称 | 中银证券 | | | 时间 2022 | 年 5 月 24 | 日 10:30-11:30 | | | 地点 公司会议室 | | | 会议形式 电话会议 | | | | 上市公司接待人 员姓名 | | 董事会秘书何仕、证券事务代表曾博茹 | | | 主要交流内容： | | | | | 一、公司基本情 ...

证券代码：603998 证券简称：方盛制药 编号：2022-005 湖南方盛制药股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-----------------------|--------------------|--------------------------------------------------------------------------------------------------------------------| | | 特定对象调研 | 分析师会议 | | | 媒体采访 | 业绩说明会 | | 投资者关系活动 | 新闻发布会 | 路演活动 | | 类别 | 现场参观 | 电话会议 | | | 其他 | | | 参与单位名称 | 国信证券、楚恒资产 | | | 时间 2022 | 年 6 月 20 | 日 9:30-12:00 | | | 地点 公司会议室 | | | 会议形式 现场调研 | | | | 上市公司接待人 员姓名 | | 董事会秘书何仕、证券事务代表曾博茹 | | | 主要交流内容： | 一、公司基本情况介绍 | | | | 公司 ...

证券代码：603998 证券简称：方盛制药 编号：2022-004 湖南方盛制药股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-----------------------|--------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------| | 投资者关系活动 \n类别 | 特定对象调研 \n 媒体采访 \n 新闻发布会 \n 现场参观 \n 其他 | 分析师会议 \n 业绩说明会 \n 路演活动 \n 电话会议 | | 参与单位名称 | 华鑫证券俞家宁 | | | 时间 2022 | 年 6 月 1 日 | 15:00-17:30 | | | 地点 公司会议室 | | | 会议形式 现场调研 | | | | 上市公司接待人 员姓名 | 董事会秘书何仕 | | | | 主要交 ...

2022 年第三季度报告 证券代码：603998 证券简称：方盛制药 湖南方盛制药股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 主要会计数据和财务指标 注:"本报告期"指本季度初至本季度末 3 个月期间，下同。 说明： 1、 公司聚焦主业，持续优化业务结构，在积极提升研发能力的同时，深化营销体系改革， 加快产品结构调整，坚持以创新驱动发展，以中药创新发展为主体，同时统筹推进化学药协同发 单位：元 币种：人民币 项目 本报告期 本报告期比上年同期 增减变动幅度(%) 年初至报告期末 年初至报告期末比上 年同期增减变动幅度 (%) 营业收入 484,325,77 ...

湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 证券代码：603998 证券简称：方盛制药 公告编号：2022-104 湖南方盛制药股份有限公司 关于参加湖南辖区上市公司2022年投资者 网上集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为进一步加强与广大投资者的沟通交流，做好投资者关系管 理工作，湖南方盛制药股份有限公司（以下简称"公司"）将参 加由中国证券监督管理委员会湖南监管局、湖南省上市公司协会 与深圳市全景网络有限公司联合举办的"湖南辖区上市公司2022 年投资者网上集体接待日"活动，现将有关事项公告如下： 本次投资者网上集体接待日活动将通过深圳市全景网络有限 公司提供的互联网平台举行，投资者可以登录"全景路演"网站 （http://rs.p5w.net）参与本次投资者网上集体接待日活动，活 动时间为：2022年9月29日（星期四）15:30至16:55。 届时公司董事会秘书何仕先生、证券事务代表曾博茹女士将 通过网络在线问答互动的形式 ...

2022 年半年度报告 公司代码：603998 公司简称：方盛制药 湖南方盛制药股份有限公司 2022 年半年度报告 2022 年 8 月 31 日 第 1 页，共 147 页 2022 年半年度报告 重要提示 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 董事会同意以公告实施利润分配的股权登记日当天的总股本为基数，向股权登记日在册全体 股东每 10 股派发 0.90 元现金红利（含税），不送红股，不进行资本公积金转增股本。以上预案 尚需股东大会审议通过。 六、 前瞻性陈述的风险声明 √适用□不适用 本报告中所涉及的未来计划、发展战略等前瞻性描述不构成公司对投资者的实质承诺，敬请 投资者注意投资风险。 七、 是否存在被控股股东及其关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况？ 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 否 十、 重大风险提示 报告期内，不存在对公司生产经营产生实质性影响的特别重大风险。公司已在本报告中详细 阐述在生产经营过程中可能面临的各种风险，详见"第三节管理层讨论与分析"之公司可能面临 的风险。 ...